UP-FOR-U

Impact of upadacitinib on uveitis in axSpA

(Recruiting soon)

Type

Interventional - treatment

Purpose

Axial spondyloarthritis (axSpA) is an inflammatory arthritis of the spine and sacroiliac joints. In addition, many people experience other symptoms of the disease such as arthritis in peripheral joints, inflammatory bowel disease, and eye inflammation (uveitis). 

The purpose of this study is to test the efficacy of approved therapy, Rinvoq, specifically for ocular symptoms. 

Eligibility

You may be eligible for this study if you:

• Are aged ≥18;
• Have been diagnosed with axial spondyloarthritis;
• Have active disease; and
• Have had at least one uveitis event in the past 2 years. 

Participation

Participants receive upadacitinib (Rinvoq) for 52 weeks. 

You will be followed over the course of treatment, with in-office visits (including physical exam, blood draw, and questionnaires) every 3 months. In between your in-office visits, you will be asked to complete questionnaires monthly.

You will receive compensation for your time at the study visits.